Health Canada accepts Cipher’s tramadol NDA for review
Health Canada accepts Cipher’s tramadol NDA for review
Monday, Mar 29, 2010 18:00 IST
Mississauga, Ontario
Cipher Pharmaceuticals Inc voiced which the New Drug Submission (NDS) to Health Canada for CIP-Tramadol ER, the extended-release plan of tramadol, has been supposed for review. The association expects the examination to be finished by early 2011.
“The Canadian marketplace for tramadol is clever as well as growing, with sales of you estimate US$ 50 million final year, the thirty per cent enlarge over the before year,” pronounced Larry Andrews, boss as well as CEO of Cipher. “With the quick fullness profile, no food effect, as well as 24-hour suffering coverage, you hold the product would yield an tasteful diagnosis choice for tolerably serious pain. This acquiescence is unchanging with the skeleton to aim one more markets for the 3 existent products.”
Cipher Pharmaceuticals is the commercial-stage drug growth association focused upon commercializing novel formulations of successful, now marketed molecules regulating modernized drug smoothness technologies.
Source:
http://www.pharmabiz.com/article/detnews.asp?articleid=54739§ionid=
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
